Alkermes Plc (ALKS) 49.19 $ALKS
Look for Shares of Alkermes to Potentially Pullback after Yesterday's 4.17% Rise
Comtex SmarTrend(R) - Thu Jul 07, 2:57PM CDT
Alkermes (NASDAQ:ALKS) traded in a range yesterday that spanned from a low of $45.99 to a high of $47.91. Yesterday, the shares gained 4.2%, which took the trading range above the 3-day high of $46.23 on volume of 508,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ALKS: 49.19 (+0.24)
After Yesterday's Rally of 3.42% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Wed Jun 22, 3:05PM CDT
Alkermes (NASDAQ:ALKS) traded in a range yesterday that spanned from a low of $41.29 to a high of $44.00. Yesterday, the shares gained 3.4%, which took the trading range above the 3-day high of $42.81 on volume of 339,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ALKS: 49.19 (+0.24)
23.0% Return Seen to Date on SmarTrend Alkermes Call (ALKS)
Comtex SmarTrend(R) - Wed Jun 08, 1:28AM CDT
SmarTrend identified an Uptrend for Alkermes (NASDAQ:ALKS) on April 6th, 2016 at $37.32. In approximately 2 months, Alkermes has returned 22.96% as of today's recent price of $45.89.
ALKS: 49.19 (+0.24)
Alkermes' Corporate Presentation to Be Webcast at the Goldman Sachs 37th Annual Global Healthcare Conference
BusinessWire - Wed Jun 01, 3:00PM CDT
Alkermes plc (NASDAQ: ALKS) announced today that its corporate presentation will be webcast live at the Goldman Sachs 37th Annual Global Healthcare Conference on Wednesday, June 8, 2016, at 1:20 p.m. PDT (4:20 p.m. EDT/9:20 p.m. BST) from the Terranea Resort in Rancho Palos Verdes, Calif. The presentation may be accessed under the Investors tab on www.alkermes.com and will be archived for 14 days.
ALKS: 49.19 (+0.24)
Shares of ALKS Up 24.4% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Wed Jun 01, 1:09AM CDT
SmarTrend identified an Uptrend for Alkermes (NASDAQ:ALKS) on April 6th, 2016 at $37.32. In approximately 2 months, Alkermes has returned 24.36% as of today's recent price of $46.41.
ALKS: 49.19 (+0.24)
SmarTrend Watching for Potential Pullback in Shares of Alkermes After 1.89% Gain
Comtex SmarTrend(R) - Tue May 31, 4:34PM CDT
Alkermes (NASDAQ:ALKS) traded in a range yesterday that spanned from a low of $45.99 to a high of $47.90. Yesterday, the shares gained 1.9%, which took the trading range above the 3-day high of $46.21 on volume of 692,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ALKS: 49.19 (+0.24)
Alkermes Begins Phase I Study on Immuno-Oncology Drug
Zacks Equity Research - Zacks Investment Research - Thu May 26, 10:30AM CDT
Alkermes (ALKS) announced the initiation of a phase I study on its immuno-oncology candidate ALKS 4230 for the treatment of solid tumors
ANIP: 55.38 (-1.13), RTRX: 18.47 (-0.18), ACOR: 25.57 (-0.64), ALKS: 49.19 (+0.24)
Alkermes Appoints Nancy Snyderman, M.D., to Board of Directors
BusinessWire - Thu May 26, 6:00AM CDT
Alkermes plc (NASDAQ: ALKS) today announced the appointment of Nancy L. Snyderman, M.D., to the company's Board of Directors. Dr. Snyderman most recently served as Chief Medical Editor at NBC News, and has more than three decades of experience as a leading voice in healthcare and medicine. Dr. Snyderman is a board certified Otolaryngologist-Head and Neck Surgeon and Fellow in the American College of Surgeons.
ALKS: 49.19 (+0.24)
Alkermes Announces Initiation of Phase 1 Clinical Study of Immuno-Oncology Drug Candidate ALKS 4230
BusinessWire - Wed May 25, 6:00AM CDT
Alkermes plc (NASDAQ: ALKS) today announced the initiation of a phase 1 clinical study of the company's immuno-oncology drug candidate, ALKS 4230 (formerly referred to as RDB 1450), a novel Selective Effector Cell Activator (SECA(TM)) protein designed for targeted interleukin-2 (IL-2) receptor activation. The multi-center phase 1 study is designed to evaluate the safety, tolerability and immunological-pharmacodynamic effects of ALKS 4230 in the treatment of patients with solid tumors.
ALKS: 49.19 (+0.24)
Alkermes to Present Data on ALKS 5461 at Upcoming American Society of Clinical Psychopharmacology Annual Meeting
BusinessWire - Tue May 24, 6:00AM CDT
---- Management Will Discuss Data and Study Design Details From FORWARD-3 and FORWARD-4, Two Phase 3 Studies of ALKS 5461 for the Treatment of Major Depressive Disorder --
ALKS: 49.19 (+0.24)
SmarTrend Watching for Potential Pullback in Shares of Alkermes After 7.46% Gain
Comtex SmarTrend(R) - Fri May 20, 2:01PM CDT
Alkermes (NASDAQ:ALKS) traded in a range yesterday that spanned from a low of $39.36 to a high of $42.84. Yesterday, the shares gained 7.5%, which took the trading range above the 3-day high of $41.13 on volume of 1.1 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ALKS: 49.19 (+0.24)
Why Investors Still See Value in Alkermes, AMAG Pharmaceuticals, IDEXX Laboratories and Atossa Genetics?
PR Newswire - Thu May 19, 7:50AM CDT
The equities market is never short of surprises, and one sector that is always abounding of surprises is without doubt the Healthcare space. ActiveWallSt.com has uncovered four stocks in the Healthcare sector ahead of today's trading session: Alkermes PLC (NASDAQ: ALKS), AMAG Pharmaceuticals Inc. (NASDAQ: AMAG), IDEXX Laboratories Inc. (NASDAQ: IDXX), and Atossa Genetics Inc. (NASDAQ: ATOS). Sign up for your complimentary alerts at:
ATOS: 0.30 (+0.02), AMAG: 25.52 (+0.33), IDXX: 94.60 (-0.36), ALKS: 49.19 (+0.24)
Alkermes (ALKS) Reports Narrower-than-Expected Q1 Loss
Zacks Equity Research - Zacks Investment Research - Fri Apr 29, 8:31AM CDT
Alkermes (ALKS) reported a loss of 32 cents per share in the first quarter of 2016, narrower than the Zacks Consensus Estimate of a loss of 43 cents.
BIIB: 252.54 (+1.24), EBS: 30.47 (+0.43), AEGR: 1.62 (-0.05), ALKS: 49.19 (+0.24)
Alkermes reports 1Q loss
Automated Insights - Thu Apr 28, 8:34AM CDT
DUBLIN (AP) _ Alkermes PLC (ALKS) on Thursday reported a loss of $77.4 million in its first quarter.
ALKS: 49.19 (+0.24)
Alkermes plc Reports First Quarter 2016 Financial Results
BusinessWire - Thu Apr 28, 6:00AM CDT
----VIVITROL(R) Net Sales Grew by 41% Year-Over-Year to $43.8 Million --
ALKS: 49.19 (+0.24)
Alkermes Announces Plan to Initiate Second Clinical Trial of ALKS 7119 Based on Preliminary Phase 1 Results
BusinessWire - Thu Apr 28, 5:58AM CDT
---- Company Accelerates Plans to Initiate Multiple-Dose Study --
ALKS: 49.19 (+0.24)
Alkermes to Host Conference Call to Discuss First Quarter 2016 Financial Results
BusinessWire - Thu Apr 21, 3:00PM CDT
Alkermes plc (NASDAQ: ALKS) will host a conference call at 8:30 a.m. EDT (1:30 p.m. BST) on Thursday, April 28, 2016, to discuss the company's first quarter 2016 financial results. Management will also provide an update on the company.
ALKS: 49.19 (+0.24)
Alkermes Has Returned 49.9% Since SmarTrend Recommendation (ALKS)
Comtex SmarTrend(R) - Tue Apr 05, 1:13AM CDT
SmarTrend identified a Downtrend for Alkermes (NASDAQ:ALKS) on January 7th, 2016 at $72.51. In approximately 3 months, Alkermes has returned 49.87% as of today's recent price of $36.35.
ALKS: 49.19 (+0.24)
Look for Shares of Alkermes to Potentially Pullback after Yesterday's 6.21% Rise
Comtex SmarTrend(R) - Thu Mar 31, 2:38PM CDT
Alkermes (NASDAQ:ALKS) traded in a range yesterday that spanned from a low of $32.02 to a high of $34.24. Yesterday, the shares gained 6.2%, which took the trading range above the 3-day high of $33.53 on volume of 627,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ALKS: 49.19 (+0.24)
Look for Shares of Alkermes to Potentially Pullback after Yesterday's 4.17% Rise
Comtex SmarTrend(R) - Thu Jul 07, 2:57PM CDT
Alkermes (NASDAQ:ALKS) traded in a range yesterday that spanned from a low of $45.99 to a high of $47.91. Yesterday, the shares gained 4.2%, which took the trading range above the 3-day high of $46.23 on volume of 508,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ALKS: 49.19 (+0.24)
After Yesterday's Rally of 3.42% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Wed Jun 22, 3:05PM CDT
Alkermes (NASDAQ:ALKS) traded in a range yesterday that spanned from a low of $41.29 to a high of $44.00. Yesterday, the shares gained 3.4%, which took the trading range above the 3-day high of $42.81 on volume of 339,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ALKS: 49.19 (+0.24)
23.0% Return Seen to Date on SmarTrend Alkermes Call (ALKS)
Comtex SmarTrend(R) - Wed Jun 08, 1:28AM CDT
SmarTrend identified an Uptrend for Alkermes (NASDAQ:ALKS) on April 6th, 2016 at $37.32. In approximately 2 months, Alkermes has returned 22.96% as of today's recent price of $45.89.
ALKS: 49.19 (+0.24)
Alkermes' Corporate Presentation to Be Webcast at the Goldman Sachs 37th Annual Global Healthcare Conference
BusinessWire - Wed Jun 01, 3:00PM CDT
Alkermes plc (NASDAQ: ALKS) announced today that its corporate presentation will be webcast live at the Goldman Sachs 37th Annual Global Healthcare Conference on Wednesday, June 8, 2016, at 1:20 p.m. PDT (4:20 p.m. EDT/9:20 p.m. BST) from the Terranea Resort in Rancho Palos Verdes, Calif. The presentation may be accessed under the Investors tab on www.alkermes.com and will be archived for 14 days.
ALKS: 49.19 (+0.24)
Shares of ALKS Up 24.4% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Wed Jun 01, 1:09AM CDT
SmarTrend identified an Uptrend for Alkermes (NASDAQ:ALKS) on April 6th, 2016 at $37.32. In approximately 2 months, Alkermes has returned 24.36% as of today's recent price of $46.41.
ALKS: 49.19 (+0.24)
SmarTrend Watching for Potential Pullback in Shares of Alkermes After 1.89% Gain
Comtex SmarTrend(R) - Tue May 31, 4:34PM CDT
Alkermes (NASDAQ:ALKS) traded in a range yesterday that spanned from a low of $45.99 to a high of $47.90. Yesterday, the shares gained 1.9%, which took the trading range above the 3-day high of $46.21 on volume of 692,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ALKS: 49.19 (+0.24)
Alkermes Begins Phase I Study on Immuno-Oncology Drug
Zacks Equity Research - Zacks Investment Research - Thu May 26, 10:30AM CDT
Alkermes (ALKS) announced the initiation of a phase I study on its immuno-oncology candidate ALKS 4230 for the treatment of solid tumors
ANIP: 55.38 (-1.13), RTRX: 18.47 (-0.18), ACOR: 25.57 (-0.64), ALKS: 49.19 (+0.24)
Alkermes Appoints Nancy Snyderman, M.D., to Board of Directors
BusinessWire - Thu May 26, 6:00AM CDT
Alkermes plc (NASDAQ: ALKS) today announced the appointment of Nancy L. Snyderman, M.D., to the company's Board of Directors. Dr. Snyderman most recently served as Chief Medical Editor at NBC News, and has more than three decades of experience as a leading voice in healthcare and medicine. Dr. Snyderman is a board certified Otolaryngologist-Head and Neck Surgeon and Fellow in the American College of Surgeons.
ALKS: 49.19 (+0.24)
Alkermes Announces Initiation of Phase 1 Clinical Study of Immuno-Oncology Drug Candidate ALKS 4230
BusinessWire - Wed May 25, 6:00AM CDT
Alkermes plc (NASDAQ: ALKS) today announced the initiation of a phase 1 clinical study of the company's immuno-oncology drug candidate, ALKS 4230 (formerly referred to as RDB 1450), a novel Selective Effector Cell Activator (SECA(TM)) protein designed for targeted interleukin-2 (IL-2) receptor activation. The multi-center phase 1 study is designed to evaluate the safety, tolerability and immunological-pharmacodynamic effects of ALKS 4230 in the treatment of patients with solid tumors.
ALKS: 49.19 (+0.24)
Alkermes to Present Data on ALKS 5461 at Upcoming American Society of Clinical Psychopharmacology Annual Meeting
BusinessWire - Tue May 24, 6:00AM CDT
---- Management Will Discuss Data and Study Design Details From FORWARD-3 and FORWARD-4, Two Phase 3 Studies of ALKS 5461 for the Treatment of Major Depressive Disorder --
ALKS: 49.19 (+0.24)
SmarTrend Watching for Potential Pullback in Shares of Alkermes After 7.46% Gain
Comtex SmarTrend(R) - Fri May 20, 2:01PM CDT
Alkermes (NASDAQ:ALKS) traded in a range yesterday that spanned from a low of $39.36 to a high of $42.84. Yesterday, the shares gained 7.5%, which took the trading range above the 3-day high of $41.13 on volume of 1.1 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ALKS: 49.19 (+0.24)
Why Investors Still See Value in Alkermes, AMAG Pharmaceuticals, IDEXX Laboratories and Atossa Genetics?
PR Newswire - Thu May 19, 7:50AM CDT
The equities market is never short of surprises, and one sector that is always abounding of surprises is without doubt the Healthcare space. ActiveWallSt.com has uncovered four stocks in the Healthcare sector ahead of today's trading session: Alkermes PLC (NASDAQ: ALKS), AMAG Pharmaceuticals Inc. (NASDAQ: AMAG), IDEXX Laboratories Inc. (NASDAQ: IDXX), and Atossa Genetics Inc. (NASDAQ: ATOS). Sign up for your complimentary alerts at:
ATOS: 0.30 (+0.02), AMAG: 25.52 (+0.33), IDXX: 94.60 (-0.36), ALKS: 49.19 (+0.24)
Alkermes (ALKS) Reports Narrower-than-Expected Q1 Loss
Zacks Equity Research - Zacks Investment Research - Fri Apr 29, 8:31AM CDT
Alkermes (ALKS) reported a loss of 32 cents per share in the first quarter of 2016, narrower than the Zacks Consensus Estimate of a loss of 43 cents.
BIIB: 252.54 (+1.24), EBS: 30.47 (+0.43), AEGR: 1.62 (-0.05), ALKS: 49.19 (+0.24)
Alkermes reports 1Q loss
Automated Insights - Thu Apr 28, 8:34AM CDT
DUBLIN (AP) _ Alkermes PLC (ALKS) on Thursday reported a loss of $77.4 million in its first quarter.
ALKS: 49.19 (+0.24)
Alkermes plc Reports First Quarter 2016 Financial Results
BusinessWire - Thu Apr 28, 6:00AM CDT
----VIVITROL(R) Net Sales Grew by 41% Year-Over-Year to $43.8 Million --
ALKS: 49.19 (+0.24)
Alkermes Announces Plan to Initiate Second Clinical Trial of ALKS 7119 Based on Preliminary Phase 1 Results
BusinessWire - Thu Apr 28, 5:58AM CDT
---- Company Accelerates Plans to Initiate Multiple-Dose Study --
ALKS: 49.19 (+0.24)
Alkermes to Host Conference Call to Discuss First Quarter 2016 Financial Results
BusinessWire - Thu Apr 21, 3:00PM CDT
Alkermes plc (NASDAQ: ALKS) will host a conference call at 8:30 a.m. EDT (1:30 p.m. BST) on Thursday, April 28, 2016, to discuss the company's first quarter 2016 financial results. Management will also provide an update on the company.
ALKS: 49.19 (+0.24)
Alkermes Has Returned 49.9% Since SmarTrend Recommendation (ALKS)
Comtex SmarTrend(R) - Tue Apr 05, 1:13AM CDT
SmarTrend identified a Downtrend for Alkermes (NASDAQ:ALKS) on January 7th, 2016 at $72.51. In approximately 3 months, Alkermes has returned 49.87% as of today's recent price of $36.35.
ALKS: 49.19 (+0.24)
Look for Shares of Alkermes to Potentially Pullback after Yesterday's 6.21% Rise
Comtex SmarTrend(R) - Thu Mar 31, 2:38PM CDT
Alkermes (NASDAQ:ALKS) traded in a range yesterday that spanned from a low of $32.02 to a high of $34.24. Yesterday, the shares gained 6.2%, which took the trading range above the 3-day high of $33.53 on volume of 627,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ALKS: 49.19 (+0.24)
